Clarus Wealth Advisors Geron Corp Transaction History

Clarus Wealth Advisors

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 08, 2020	SELL	$0.89 - $1.49 $16,910 - $28,310	-19,000 Closed	0 $0
Q3 2018 Oct 03, 2018	BUY	$1.76 - $6.38 $7,040 - $25,520	4,000 Added 26.67%	19,000 $33,000
Q4 2017 Feb 05, 2018	BUY	$1.8 - $2.32 $27,000 - $34,800	15,000	15,000 $27,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Clarus Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Clarus Wealth Advisors with notifications on news.